Here we go again: COVID-19 hospital admissions have inched upward in the United States since early July in a small-scale echo of the three previous summers.
With an updated vaccine still months away, this summer bump in new hospitalizations might be concerning, but the number of patients is far lower than before. A look at what we know:
HOW BAD IS THE SPIKE?
For the week ending July 29, COVID-19 hospital admissions were at 9,056. That's an increase of about 12% from the previous week.
But it's a far cry from past peaks, like the 44,000 weekly hospital admissions in early January, the nearly 45,000 in late July 2022, or the 150,000 admissions during the omicron surge of January 2022.
“It is ticking up a little bit, but it’s not something that we need to raise any alarm bells over,” said Dr. David Dowdy, an infectious disease epidemiologist at Johns Hopkins Bloomberg School of Public Health.
It’s likely that infections are rising too, but the data is scant. Federal authorities ended the public health emergency in May, so the Centers for Disease Control and Prevention and many states no longer track the number of positive test results.
WHAT ABOUT DEATHS?
Since early June, about 500 to 600 people have died each week. The number of deaths appears to be stable this summer, although past increases in deaths have lagged behind hospitalizations.
HOW ARE WE TRACKING THE VIRUS?
The amount of the COVID-19 virus in sewage water has been rising since late June across the nation. In the coming weeks, health officials say they'll keep a close eye on wastewater levels as people return from summer travel and students go back to school.
Higher levels of COVID-19 in wastewater concentrations are being found in the Northeast and South, said Cristin Young, an epidemiologist at Biobot Analytics, the CDC's wastewater surveillance contractor.
“It’s important to remember right now the concentrations are still fairly low,” Young said, adding it's about 2.5 times lower than last summer.
“There are a couple that we’re watching, but we’re not seeing anything like delta or omicron,” Young said, referencing variants that fueled previous surges.
And mutations in the virus don't necessarily make it more dangerous.
“Just because we have a new subvariant doesn’t mean that we are destined to have an increase in bad outcomes," Dowdy said.
WHEN IS THE NEW VACCINE COMING?
This fall, officials expect to see updated COVID-19 vaccines that contain one version of the omicron strain, called XBB.1.5. It’s an important change from today’s combination shots, which mix the original coronavirus strain with last year’s most common omicron variants.
It's not clear exactly when people can start rolling up their sleeves for what officials hope is an annual fall COVID-19 shot. Pfizer, Moderna and smaller manufacturer Novavax all are brewing doses of the XBB update but the Food and Drug Administration will have to sign off on each, and the CDC must then issue recommendations for their use.
Dr. Mandy Cohen, the new CDC director, said she expects people will get their COVID-19 shots where they get their flu shots — at pharmacies and at work — rather than at dedicated locations that were set up early in the pandemic as part of the emergency response.
“This is going to be our first fall and winter season coming out of the public health emergency, and I think we are all recognizing that we are living with COVID, flu, and RSV," Cohen told The Associated Press last week. “But the good news is we have more tools than ever before.”
AP Medical Writers Lauran Neergaard and Mike Stobbe contributed to this report.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Healthcare workforce management platform ShiftMed
recently announced a $45 million funding round.
The company's platform connects nurses and healthcare professionals to hospitals and other healthcare providers.
ShiftMed's new funding comes amid widespread labor shortages in the healthcare sector. The company's CEO Todd Walrath joins Cheddar News' Closing Bell to discuss.
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
Supply chain issues have become one of the biggest roadblocks for the U.S. EV market, with production woes likely to stunt the industry's growth in 2022. Rich Steinberg, electric vehicle expert and industry advisor, told Cheddar that the Biden administration investing in domestic mining for essential minerals used in battery manufacturing — such as lithium — could help alleviate the bottlenecks. "Some of those same materials are available domestically, they just haven't been prioritized," he said, noting the paradox between green tech and "dirty" mining. "The good news is that there are ways to extract those materials cleanly."
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
Dr. Rob Davidson, Executive Director of the Committee to Protect Health Care and an ER Physician in West Michigan, joins Cheddar News to break down the expectations of Pfizer's new COVID-19 treatment pill.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
